Means and methods for influencing the stability of antibody producing cells
AssigneesAcademisch Medisch Centrum bij de Universiteit van Amsterdam, Aimm Therapeutics B.V.
InventorsHergen Spits, Ferenc A. Scheeren, Tim Beaumont, Sean A. Diehl
Life of this patent
Estimating the term…
Abstract
The invention provides a method for influencing the stability of an antibody producing cell, comprising directly or indirectly influencing the amount of BCL6 and/or Blimp 1 expression product within said antibody producing cell. Stable antibody producing cells and cell lines are also provided, as well as methods for producing antibodies using such cells and/or cell lines.
Claims20
A method for producing an antibody producing cell culture that is able to replicate for at least one week, the method comprising:
- providing a B cell;
- increasing an expression level of Blimp-1 in said B cell by culturing the B cell in the presence of IL-21 and/or IL-10, or by providing the B cell with STAT3;
- providing the B cell with a nucleic acid molecule encoding a peptide comprising BCL6;
- and
- providing the B cell with a nucleic acid molecule encoding BCL-xL.
A method for producing an antibody producing cell culture able to replicate for at least one week, wherein the antibody producing cell expresses a level of Blimp-1, the method comprising:
- increasing the expression level of Blimp-1 in the antibody producing cell by culturing the antibody producing cell in the presence of IL-21 and/or IL-10, or by providing the antibody producing cell with STAT3;
- providing the antibody producing cell with a nucleic acid molecule encoding a peptide comprising BCL6;
- and
- providing the antibody producing cell with a nucleic acid molecule encoding BCL-xL.
A method for producing an antibody producing cell that is able to replicate for at least one week, the method comprising:
- providing an antibody producing cell with a polynucleotide encoding a peptide comprising BCL6 to enhance the antibody producing cell's stability;
- culturing the antibody producing cell with IL-21, IL-10, and/or STAT3 to increase expression of Blimp-1 in the antibody producing cell;
- and
- providing the antibody producing cell with a polynucleotide encoding BCL-xL.
Dependencies are inferred from the claim text.